{"disease":{"id":"severe-hereditary-factor-viii-deficiency-disease","name":"Severe hereditary factor VIII deficiency disease","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"valoctocogene-roxaparvovec","indication_name":"Severe hereditary factor VIII deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Roctavian","generic_name":"VALOCTOCOGENE ROXAPARVOVEC","company_name":"BioMarin International Limited","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":43,"revenue":null,"mechanism":"Roctavian introduces a functional copy of the F8 gene into cells to produce factor VIII protein."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04165135","title":"An Observational Study to Evaluate Physical Activity, Bleeding Incidence and Health Related Quality of Life, in Participants With Haemophilia A Without Inhibitors Receiving Standard of Care Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":103,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}